https://www.selleckchem.com/pr....oducts/emd-1214063.h
ially for different US tumor size. The ALNFM could effectively predict ALN status based on US images especially for different US tumor size.[This corrects the article DOI 10.3389/fonc.2020.571565.]. Osteosarcoma (OTS) is aggressive bone malignancy without well-recognized prognosis biomarker. Tumor mutational burden (TM has been proved as effective biomarker in predicting clinical outcomes in several cancer types. However, its prognostic value in OTS remains unknown. In this study, we aim to evaluate the implication of TMB in OTS p
Like
Comment
Share
